SMARCB1 and neoplasm: Only two somatic mutations were identified in the tumor DNA: a loss of function in the SMARCB1 gene, c.769C > T; p.(Gln257Ter), with a variant allelic frequency (VAF) of 96.3%, and a missense-damaging mutation in PTEN (c.510T > G; p.(Ser170Arg), VAF = 93.6%).